
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Bristol-Myers Squibb CEO Giovanni Caforio took to the center stage at the Cowen Health Care Conference today and tried his very best to kick out at least one of the legs holding up the persistent case being made against the big Celgene buyout.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.